Article Text

Download PDFPDF
Some concerns from Turkey
  1. Emre Bilgin1,
  2. İrem Ozarli2,
  3. Levent Kılıç1,
  4. Ertuğrul Çağrı Bölek1,
  5. Gözde Kübra Yardımcı1,
  6. Ömer Karadağ1
  1. 1 Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey
  2. 2 Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey
  1. Correspondence to Dr Emre Bilgin, Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey; dr.emrebilgin{at}gmail.com

Statistics from Altmetric.com

We read the paper written by Kaneko et al with great interest.1 This study demonstrates the safety and efficacy of tocilizumab in patients with adult-onset Still’s disease (AOSD). This randomised placebo-controlled study could be one of the pioneer studies about the use of biological therapy in AOSD. We wanted to ask about some raising concerns.

ACR20, ACR50 and ACR70 responses were used as composite indexes to assess disease activity. In the studies which investigate the effectiveness of a biologic agent in rheumatoid arthritis, general approach is to allow non-steroidal anti-inflammatory drugs (NSAID) if the dose had been stable for a while.2 However, we could not find any data of NSAIDs …

View Full Text

Footnotes

  • Handling editor Josef S Smolen

  • Contributors All authors contributed equally.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correspondence response
    Yuko Kaneko Hideto Kameda Kei Ikeda Tomonori Ishii Kosaku Murakami Hyota Takamatsu Yoshiya Tanaka Takayuki Abe Tsutomu Takeuchi